Ann M.  Leen net worth and biography

Ann Leen Biography and Net Worth

Insider of AlloVir
Dr. Ann Leen co-founded and serves as Chief Scientific Officer of AlloVir. For more than 20 years, Dr. Leen has led innovative discovery and translational research focused on developing novel T cell-based therapies. Her research has enabled multiple cell therapy programs to move from bench to bedside. She is currently the principal investigator (PI) on 5 investigator-initiated Investigational New Drug (IND) studies and over the past 10 years has served as PI on more than 10 clinical trials using “first in man” cell therapies for patients.

In addition to her role at AlloVir, Dr. Leen continues to serve as Professor in the Department Pediatrics at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, where she has held various faculty positions since 2005. She is senior or co-author on more than 90 publications and a named inventor on 14 published patents.

Ann received her B.S. in Biochemistry at the University of College Cork in Cork, Ireland and her Ph.D. in Immunology at the CRC Institute for Cancer Studies in Birmingham, UK.

What is Ann M. Leen's net worth?

The estimated net worth of Ann M. Leen is at least $11,817.07 as of May 10th, 2021. Dr. Leen owns 1,217 shares of AlloVir stock worth more than $11,817 as of February 10th. This net worth evaluation does not reflect any other assets that Dr. Leen may own. Learn More about Ann M. Leen's net worth.

How old is Ann M. Leen?

Dr. Leen is currently 46 years old. There are 7 older executives and no younger executives at AlloVir. The oldest executive at AlloVir is Mr. Vikas Sinha C.A., CPA, M.B.A., President, CFO & Director, who is 61 years old. Learn More on Ann M. Leen's age.

How do I contact Ann M. Leen?

The corporate mailing address for Dr. Leen and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at ir@allovir.com. Learn More on Ann M. Leen's contact information.

Has Ann M. Leen been buying or selling shares of AlloVir?

Ann M. Leen has not been actively trading shares of AlloVir during the last ninety days. Most recently, Ann M. Leen sold 266 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $504.16, for a transaction totalling $134,106.56. Learn More on Ann M. Leen's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 46 times. They sold a total of 4,971 shares worth more than $82,278.96. The most recent insider tranaction occured on January, 23rd when General Counsel Edward Miller sold 52 shares worth more than $494.00. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 1/23/2025.

Ann M. Leen Insider Trading History at AlloVir

See Full Table

Ann M. Leen Buying and Selling Activity at AlloVir

This chart shows Ann M Leen's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

AlloVir Company Overview

AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.71
Low: $9.61
High: $10.16

50 Day Range

MA: $10.29
Low: $8.77
High: $12.22

2 Week Range

Now: $9.71
Low: $7.96
High: $24.15

Volume

20,504 shs

Average Volume

37,427 shs

Market Capitalization

$48.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65